Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up before the market opened on Monday . The stock had previously closed at $25.33, but opened at $26.36. Ascentage Pharma Group International shares last traded at $25.83, with a volume of 1,165 shares traded.

Wall Street Analysts Forecast Growth

AAPG has been the topic of a number of analyst reports. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. BTIG Research reaffirmed a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Monday. Finally, Rodman & Renshaw initiated coverage on Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the company’s stock. Based on data from MarketBeat, Ascentage Pharma Group International presently has an average rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Price Performance

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The company has a fifty day moving average of $24.15 and a two-hundred day moving average of $28.65.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $24.72 million during the quarter.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new position in Ascentage Pharma Group International in the third quarter valued at approximately $383,000. XY Capital Ltd boosted its stake in Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the period. UBS Group AG boosted its stake in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the period. ABC Arbitrage SA acquired a new position in Ascentage Pharma Group International in the third quarter valued at approximately $204,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Ascentage Pharma Group International in the third quarter valued at approximately $96,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.